This site needs JavaScript to work properly.

We aimed to focus on older patients with follicular lymphoma (FL) as the standard of care is evolving for these patients. During the 60th American Society of Hematology Annual Meeting and Exposition in San Diego, California, researchers presented findings from a time-and-cost simulation of subcutaneous rituximab (Rituxan Hycela), brand-name IV rituximab (Rituxan), and biosimilar IV rituximab from the US payer perspective. Gunjan L. Shah, Aaron Winn, Pei-Jung Lin, Anita J Kumar, Susan K Parsons; Comparison of Survival and Costs of Rituximab-Based Chemotherapy for Initial Therapy of Follicular Lymphoma in Elderly Patients. Substantial annual cost savings of nearly £140,000 were achieved once the switch process completed.

However, there is little literature evaluating the differences in survival and cost of care between first line rituximab-based combinations. Taylor & Francis 2010;28(1):35-46. doi: 10.2165/11314070-000000000-00000.Expert Rev Pharmacoecon Outcomes Res. Epub 2013 Nov 3.Springerplus. 2010 Nov-Dec;23(6):1025-34. 2009 Sep;13 Suppl 2:41-8. doi: 10.3310/hta13suppl2/06.Soini EJ, Martikainen JA, Vihervaara V, Mustonen K, Nousiainen T.Clin Ther. Epub 2018 Apr 24.Pharmacoeconomics.

Please enable it to take advantage of the complete set of features! 2015 Jun;33(6):551-60. doi: 10.1007/s40273-015-0260-4.Guest JF, Panca M, Sladkevicius E, Gough N, Linch M.Sarcoma. Conclusion: Our experience of switching rituximab patients is certainly not as smooth as it was for infliximab and etanercept.

PHARMAC is seeking your feedback on a proposal to make changes to the funded brand of rituximab, a biologic medicine used to treat a range of cancer, blood and autoimmune conditions, from 1 March 2020.Closes: 12pm, Thursday 14 November 2019.

For patients who lived less than 2 years, the mean monthly costs were similar between R-Chemo [$7,700 (5Overall SurvivalByRituximab Containing Induction Regimens in FLOverall SurvivalByRituximab Containing Induction Regimens in FLAsterisk with author names denotes non-ASH members. 2013;2013:725305. doi: 10.1155/2013/725305. Search for other works by this author on: Search for other works by this author on: Effects and costs were discounted at a 3% annual rate. COVID-19 is an emerging, rapidly evolving situation. Phase 3 randomized trials have shown that rituximab maintenance (MR) therapy or radio-immunotherapy (RIT) consolidation following frontline therapy can improve progression-free survival for patients with follicular lymphoma (FL), but the cost-effectiveness of these approaches with respect to observation has not been examined using a common modeling framework. Introduction: The addition of rituximab to combination chemotherapy has been shown to be cost-effective in the care of lymphoma patients. Unable to load your collection due to an error The stability of the base case results were tested in one-way and probabilistic sensitivity analyses. Search for other works by this author on: Epub 2012 Nov 11.Wang HI, Roman E, Crouch S, Aas E, Burton C, Patmore R, Smith A.Value Health. 902. doi: 10.1016/j.clinthera.2012.02.019.

Search for other works by this author on: Health Services Research-Malignant Conditions: Poster I Unable to load your delegates due to an error Epub 2010 Dec 28.Boland A, Bagust A, Hockenhull J, Davis H, Chu P, Dickson R.Health Technol Assess. The ORBIT study reported that annual costs decreased by ~20% when rituximab was used instead of a TNF-α inhibitor in patients with rheumatoid arthritis 21. OBJECTIVES. Taylor & Francis

In our cohort, home administration is associated with a cost saving of 146 592 euros (842 euros per injection, 3758 euros per patient), to which we must add patients' transport cost.

2012 Apr;34(4):915-925.e2. Name must be less than 100 characters Epub 2012 Mar 27.Pharmacoeconomics. Conclusion Our study showed that home administration of subcutaneous rituximab is feasible, safe, and well tolerated, leading to an alternative to standard hospitalization. 2018 Oct;21(10):1176-1185. doi: 10.1016/j.jval.2018.03.007. eCollection 2013.Pharmacoeconomics. Results: The evaluation assessed rituximab maintenance therapy to be associated with an incremental cost per QALY gained of euro 12,600 and an incremental cost per LYG of euro 11,200.

Search for other works by this author on: 2012 Oct;12(5):569-77. doi: 10.1586/erp.12.57. Total mean costs from diagnosis until death were $130,300 in R-CHOP treated patients, $114,800 in R-Chemo, and $108,000 in R alone.

All were happy to switch after receiving a letter and having the opportunity to contact if necessary. Clipboard, Search History, and several other advanced features are temporarily unavailable.

Braga P, Carvalho S, Gomes M, Guerra L, Lúcio P, Marques H, Negreiro F, Pereira C, Silva C, Teixeira A.Acta Med Port. 2012 Jul 1;30(7):537-49. doi: 10.2165/11591160-000000000-00000. 2013 Oct 17;2:531. doi: 10.1186/2193-1801-2-531.